BOSTON–(BUSINESS WIRE)–NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop novel and transformative therapeutics, today announced that Dominique Verhelle, Ph.D., Co-Founder, Chief Executive Officer and Chief Scientific Officer, will give a corporate presentation at the 5th Annual RNA-Targeted Drug Discovery Summit, which will be held December 13 – 15, 2022 in Boston.
Dr. Verhelle’s presentation, which is scheduled to take place on Thursday, December 15 at 1:15 p.m., will explore NextRNA’s proprietary target and drug discovery engine to identify, validate and disrupt disease-relevant interactions between long non-coding RNAs and RNA-binding proteins with small molecules.
About NextRNA Therapeutics
NextRNA is a biotechnology company unlocking the potential of non-coding RNAs to develop transformative medicines for multiple diseases. The company is leveraging its proprietary technology platform to identify non-coding RNAs and their interacting proteins responsible for disease, and to develop selective small molecules to disrupt these interactions.
For more information, please visit www.nextrnatx.com.
Contacts
Media:
Liz Melone
[email protected]
